• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    $1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

    6/14/24 7:15:34 AM ET
    $ACRS
    $CATX
    $ZOM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ACRS alert in real time by email

    The Dow Jones index closed lower by around 0.2% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

    Aclaris Therapeutics

    • The Trade: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) 10% owner Braden Michael Leonard bought a total of 1,611,200 shares at an average price of $1.11. To acquire these shares, it cost around $1.78 million.
    • What's Happening: On May 7, Aclaris Therapeutics posted upbeat quarterly results.
    • What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.

    Zomedica

    • The Trade: Zomedica Corp. (NYSE:ZOM) Vice President of Sales Russell Kevin Klass acquired a total of 299,993 shares at an average price of $0.16. To acquire these shares, it cost around $46,529.
    • What's Happening: On May 15, Zomedica announced the launch of Over-the-Air software and firmware update capability for its TRUFORMA point-of-care diagnostic platform.
    • What Zomedica Does: Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.

    Perspective Therapeutics

    • The Trade: Perspective Therapeutics, Inc. (NASDAQ:CATX) CEO Johan M. Spoor acquired a total of 100,000 at an average price of $1.17. The insider spent around $117,430 to buy those shares.
    • What's Happening: On June 11, Perspective Therapeutics announced a 1-for-10 reverse stock split.
    • What Perspective Therapeutics Does: Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body.

    Now Read This: Top 3 Tech Stocks That May Fall Off A Cliff This Month

    Get the next $ACRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRS
    $CATX
    $ZOM

    CompanyDatePrice TargetRatingAnalyst
    Aclaris Therapeutics Inc.
    $ACRS
    4/16/2026$10.00Outperform
    Oppenheimer
    Perspective Therapeutics Inc.
    $CATX
    2/19/2026$16.00Overweight
    Piper Sandler
    Perspective Therapeutics Inc.
    $CATX
    11/24/2025$12.00Buy
    Truist
    Perspective Therapeutics Inc.
    $CATX
    10/10/2025$14.00Buy
    BTIG Research
    Aclaris Therapeutics Inc.
    $ACRS
    7/10/2025$6.00Overweight
    Piper Sandler
    Aclaris Therapeutics Inc.
    $ACRS
    5/28/2025$8.00Outperform
    Wedbush
    Aclaris Therapeutics Inc.
    $ACRS
    3/18/2025Overweight
    Cantor Fitzgerald
    Perspective Therapeutics Inc.
    $CATX
    3/13/2025$10.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACRS
    $CATX
    $ZOM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

    WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday, April 14, 2026, at 12:00 PM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days

    4/8/26 8:30:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perspective Therapeutics to Participate in Upcoming Investor Conferences

    SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences: 25th Annual Needham Virtual Healthcare Conference – Presentation & Fireside ChatDate: Tuesday, April 14, 2026Time: 9:30-10:10 a.m. ET Location: Virtual Piper Sandler Spring Biopharma Symposium – 1x1s onlyDate: Thursday, April 16, 2026Location: Boston, MA About Perspective Therapeutics, Inc.

    4/2/26 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

    - Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life - WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today provided additional results from its Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of ITK and Janus kinase 3 (JAK3), presented in an electronic poster at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO. "We have continued to achieve importan

    3/27/26 10:10:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $CATX
    $ZOM
    SEC Filings

    View All

    SEC Form DEFA14A filed by Perspective Therapeutics Inc.

    DEFA14A - Perspective Therapeutics, Inc. (0000728387) (Filer)

    4/16/26 4:10:52 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by Perspective Therapeutics Inc.

    DEF 14A - Perspective Therapeutics, Inc. (0000728387) (Filer)

    4/16/26 4:10:05 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Aclaris Therapeutics Inc.

    SCHEDULE 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    4/7/26 5:59:55 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $CATX
    $ZOM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Aclaris Therapeutics with a new price target

    Oppenheimer initiated coverage of Aclaris Therapeutics with a rating of Outperform and set a new price target of $10.00

    4/16/26 8:02:28 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Perspective Therapeutics with a new price target

    Piper Sandler initiated coverage of Perspective Therapeutics with a rating of Overweight and set a new price target of $16.00

    2/19/26 7:52:02 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Truist resumed coverage on Perspective Therapeutics with a new price target

    Truist resumed coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $12.00

    11/24/25 9:17:24 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $ACRS
    $CATX
    $ZOM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Martinez Maria E

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    3/4/26 4:38:30 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Morich Frank

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    3/4/26 4:38:07 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Williamson Robert F Iii

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    3/4/26 4:37:44 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $ACRS
    $CATX
    $ZOM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Hunt Jonathan Robert bought $22,295 worth of shares (11,000 units at $2.03), increasing direct ownership by 23% to 59,800 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/17/25 8:01:56 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Director Williamson Robert F Iii bought $19,946 worth of shares (9,498 units at $2.10) (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/14/25 8:00:03 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    4/1/25 6:44:41 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $ACRS
    $CATX
    $ZOM
    Leadership Updates

    Live Leadership Updates

    View All

    Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

    - Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis (AD). Top line results are expected in the fourth quarter of 2026. "The strong interest in participating in this Phase 2 trial reflects the urgent need for innovative solutions in atopic dermatitis and the excitement surrou

    3/18/26 6:55:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

    SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms. Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed

    9/4/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $ACRS
    $CATX
    $ZOM
    Financials

    Live finance-specific insights

    View All

    Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 - - Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis (AD) and Asthma Underway; Top Line Results from Both Trials Anticipated in the Second Half of 2026 - - Investigational New Drug (IND) Application for Lead ITK Inhibitor Candidate ATI-9494 Expected in the SecondHalf of 2026 - - ATI-2138, Aclaris' Investigational Inhibitor of ITK and JAK3, Demonstrated Potential Best-in-Class Hair Regrowth in Murine Alopecia Model -  WAYNE, Pa., Feb. 26,

    2/26/26 6:58:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

    - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage of ATI-052 - - Trial Results Support Potential for Extended Dosing of up to Every Three Months - - Initiation of Phase 1b Proof-of-Concept (POC) Trials in Atopic Dermatitis (AD) and Asthma Now Expected in First Quarter of 2026; Planning Underway for Advancement of ATI-052 into Phase 2b Trial in AD in the Second Half of 2026 - - Management to Host a Conference Call to Discuss Update Today at 8:00 AM EST - WAYNE, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on

    1/6/26 6:59:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    - Positive Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, Further Validating ITK as Therapeutic Target; Initiation of Phase 2 Trial in an Additional Indication Expected in the First Half of 2026 - - Timelines Reiterated for Top Line Clinical Results from Ongoing Trials of Investigational Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) and Anti-TSLP/IL-4R Bispecific Antibody ATI-052 - - Initiation of Phase 1b Proof-of-Concept Trials of ATI-052 in Asthma and Atopic Dermatitis (AD) Expected in the First Half of 2026 - - Strong Cash Runway Expected to Fund Operations into the Second Half of 20

    11/6/25 6:59:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $CATX
    $ZOM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/25/24 11:02:19 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/22/24 4:00:23 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/21/24 4:51:50 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care